# AALL1732 (NCT03959085)

> Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

No report yet. It can be ordered.

- Drugs tested: inotuzumab ozogamicin
- Indication: high-risk B-ALL, mixed phenotype acute leukemia, B-LLy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03959085
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Children's Oncology Group
- Conditions: B Acute Lymphoblastic Leukemia; B Lymphoblastic Lymphoma; Central Nervous System Leukemia; Mixed Phenotype Acute Leukemia; Testicular Leukemia
- Interventions: Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration; Bone Marrow Biopsy; Bone Scan; Calaspargase Pegol; Computed Tomography; Cyclophosphamide; Cytarabine; Daunorubicin Hydrochloride; Dexamethasone; Doxorubicin Hydrochloride; Inotuzumab Ozogamicin; Leucovorin Calcium; Magnetic Resonance Imaging; Mercaptopurine; Methotrexate; Pegaspargase; Positron Emission Tomography; Prednisolone; Prednisone; Questionnaire Administration; Radiation Therapy; Radiation Therapy; Thioguanine; Vincristine Sulfate
- Enrollment: 5951
- Primary outcome: Post-induction 5-year event-free survival (EFS)

## Indexed commentary on AALL1732 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 1
- Podcasts: 1
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=aall1732-nct03959085